Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03026257 · ClinicalTrials.gov registry record · NA
Clinical Assessment of a HYDRAGLYDE® Regimen
A NA study of Myopia and Refractive Errors, sponsored by Alcon, a Novartis Company.
- Completed
- Registry status
- NA
- Development phase
- 323
- Enrollment target
- 8
- Study locations
NCT03026257: Completed NA study of Myopia and Refractive Errors, sponsored by Alcon, a Novartis Company.
NCT03026257 is a NA study of Myopia and Refractive Errors that has completed, run by Alcon, a Novartis Company. The registered enrollment target is 323 participants, above the 264-participant average among 90 other Myopia trials with a reported enrollment target (22% higher). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03026257, a NA study of Myopia and Refractive Errors, has completed, sponsored by Alcon, a Novartis Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 323 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the control habitual silicone hydrogel (SiHy) lenses cleaned and disinfected with habitual multi-purpose solution (MPS) for cholesterol uptake.
Primary Outcome
The contact lens worn in the right eye was removed and stored dry and frozen until analysis. Total cholesterol uptake (cholesterol and cholesterol esters) was evaluated from a sample of the right contact lenses from each site and measured in micrograms. Lower total cholesterol uptake indicates increased lens performance.
Conditions Studied
Interventions
- DEVICE Lotrafilcon B contact lenses with added wetting agent
- DEVICE Samfilcon A contact lenses
- DEVICE POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent
- DEVICE Hydrogen peroxide-based contact lens solution with added wetting agent
- DEVICE Senofilcon C contact lenses
Study Locations (8)
Ohio
- Alcon Investigative Site - Cleveland
- Alcon Investigative Site - Columbus
Other
- Alcon Investigative Site - Hildesheim
- Alcon Investigative Site - Jena
Alabama
- Alcon Investigative Site - Birmingham
Tennessee
- Alcon Investigative Site - Memphis
Texas
- Alcon Investigative Site - Houston
Ontario
- Alcon Investigative Site - Waterloo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2017-08-18 |
| Phase | NA |
What the finished NCT03026257 record still lists
NCT03026257 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, above the 264-participant average among 90 other Myopia trials with a reported enrollment target (22% higher).
The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 5 interventions - of which Lotrafilcon B contact lenses with added wetting agent is the first listed.
NCT03026257 lists 8 locations in 6 states (Ohio, Other, Alabama).
Frequently Asked Questions
What is clinical trial NCT03026257 about?
NCT03026257 is a clinical study titled "Clinical Assessment of a HYDRAGLYDE® Regimen". The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the control habitual silicone hydrogel (SiHy) lenses cleaned and disinfected with habitual multi-purpose solution (MPS) for c...
What is the current status of trial NCT03026257?
This trial is currently completed. It is a NA study. The enrollment target is 323 participants. The study started on 2017-02-13. Estimated completion is 2017-08-18.
What conditions does trial NCT03026257 study?
This clinical trial studies the following conditions: Myopia, Refractive Errors, Hypermetropia.
What interventions are being tested in trial NCT03026257?
The interventions under investigation include: Lotrafilcon B contact lenses with added wetting agent (DEVICE), Samfilcon A contact lenses (DEVICE), POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent (DEVICE), Hydrogen peroxide-based contact lens solution with added wetting agent (DEVICE), Senofilcon C contact lenses (DEVICE).
Who is sponsoring clinical trial NCT03026257?
This trial is sponsored by Alcon, a Novartis Company, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03026257 being conducted?
This trial has 8 study locations across Alabama, Ohio, Tennessee, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03026257's enrollment target sits among peer trials
323 16th of 90 higher than 75 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI